Rivastigmine in Mild Alzheimer's Disease, FMRI Study — ADFRMI  

Alzheimer' Disease Clinical Trial

Official title: Effect of Rivastigmine on FMRI in Mild Alzheimer's Disease

Status Completed

Clinical Trial Summary

The purpose of the study is to investigate the effect of rivastigmine given as an acute dose compared to placebo and after 1 month chronic dosing on fMRI response during a face recognition task. Furthermore, the aim is to investigate whether fMRI response is correlated with long term treatment effect at 6 months and 12 months.

Clinical Trial Description

n/a

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Basic Science

Related Conditions & MeSH terms

• Alzheimer Disease
• Alzheimer' Disease

• NCT number: NCT00627848
• Study type: Interventional
• Source: Kuopio University Hospital
• Status: Completed
• Phase: N/A
• Start date: March 2007
• Completion date: December 2008